(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Q2 Earnings: Regeneron and Cigna Outperform Expectations

  • August 03rd, 2023
  • 485 views

Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) surged over 5% in pre-market trading following an impressive second quarter 2023 earnings report. The company exceeded expectations, reporting adjusted earnings per share (EPS) of $10.24 and revenues of $3.16 billion, surpassing the consensus estimates of $9.84 on revenues of $3.01 billion.

In pre-market, $REGN was trading at $778.10, reflecting a gain of $45.98 (+6.28%).

In a separate development, The Cigna Group (NYSE: CI) unveiled its Q2 2023 financial results, with adjusted EPS of $6.13 and revenues of $48.62 billion, outperforming the consensus estimate of $6.02 on revenue of $47.31 billion.

Looking ahead, the company provided an optimistic outlook for full-year 2023 adjusted EPS, targeting at least $24.70, surpassing the consensus projection of $24.69.

$CI was trading at $299.80 in pre-market, up $0.40 (+0.13%)

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Tags

Social Shares

Post Your Comments

Want To Find Some News?

Recent Posts

News By Industries

Tags